Why Repligen Corporation (RGEN) stock moved
Why Repligen Corporation (RGEN) rose 6.5% on November 18, 2026
Repligen Corporation (RGEN) rose 6.5% on November 18, 2026, closing at $172.67 versus $162.18 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no major company-specific catalyst was found. Volume was 1.8x the 5-day average, modestly elevated; a minor institutional position establishment (Ethic Inc. acquiring ~3,054 shares) was noted but does not explain the magnitude of the move. Source: FMP price data; BestStocks detection.
Repligen Corporation (RGEN) moved +5.91% from $163.03 to $172.67 on 2026-11-18. We checked news, earnings, analyst updates, filings, and corporate actions — no major company-specific catalyst was found. Volume was 1.8x the 5-day average, modestly elevated; a minor institutional position establishment (Ethic Inc. acquiring ~3,054 shares) was noted but does not explain the magnitude of the move.
What to watch next: Monitor for earnings on 2027-02-23 and any analyst updates ahead of that announcement.
Earlier sessions that moved RGEN
- −3.0%Amid broader sector softness in life sciences and biotech tools (Illumina, Revvity, ICON also lower today per web search).
- −3.5%Repligen Corporation (NASDAQ: RGEN) is trading down roughly 3.3% to $166.91 as of mid-morning on November 12, 2026, pulling back from its previous close of $172.62.
- +3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −5.5%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −6.2%Repligen Corporation fell 6.2% on October 30, 2026, following the announcement of a $1 billion private convertible senior notes offering due 2031, coupled with a concurrent $120 million share repurchase program. Read the October 30, 2026 analysis →
- +5.1%After reporting Q3 2026 earnings that beat consensus.
- −2.4%Repligen Corporation (RGEN) reported EPS of $0.53 vs. consensus estimate of $0.46, beating by 14.5% on 2026-10-27.
- −4.8%RGEN moved -3.66% from its $182.09 open to a $175.42 close on 2026-10-16.
- +3.4%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- +6.1%Repligen completed its $1.5 billion acquisition of BioLife Solutions on October 6, 2026, expanding into cell-therapy tools and biopreservation markets.
- −4.4%After the company completed its acquisition of BioLife Solutions.
- −7.7%Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing.
- +4.3%We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −7.8%Volume of 1.47x normal suggests active selling despite the positive earnings surprise, indicating a sell-the-news or guidance-driven reaction.
- +3.3%Repligen Corporation (RGEN) stock is up today because it is continuing a multi-week momentum surge that pushed the stock to a new 52-week high of $190.01.While there is no new company-specific catalyst filed today, the upward movement is driven by a broader wave of investor optimism, recent Wall Street price target upgrades (including Argus raising its target to $196.00), and continued positive sentiment from its raised 2026 financial guidance and pending BioLife Solutions acquisition.
Repligen Corporation (RGEN) shares fell 0.8% to $171.37 as of November 19, 2026, a slight decline from the prior close of $172.67. BestStocks flagged the session as a major change for RGEN. The move is tied to price move up. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RGEN fell 0.8% to $171.37
RGEN fell 0.8% in its latest session, moving from $172.67 to $171.37.
What it means for Repligen Corporation investors
For Repligen Corporation investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Negative session, down 0.8%. Wall Street's consensus price target sits at $198.00, implying +15.5% upside from $171.37. BestStocks rates the overall signal quality weak (32/100). With earnings roughly 96 days out, the next report is the most likely near-term test of the move.
RGEN price reaction
RGEN last traded at $171.37, down $1.30 (-0.75%) from the previous close of $172.67. The session traded on 0.4× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $162.18 and $188.64, and it currently sits about 35% of the way up that band.
Bullish and bearish analyst opinions on Repligen Corporation (RGEN)
The consensus analyst price target on Repligen Corporation (RGEN) is $198.00, 15.5% above the recent $171.37. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.
The bullish case
- Wall Street's consensus price target of $198.00 implies +15.5% upside from $171.37.
- The Street's most bullish target is $225.00 (+31.3%).
- Positive price momentum.
The bearish case
- The most bearish analyst target is $160.00 (-6.6%).
- Material negative event.
- Negative session, down 0.8%.
- Repligen announced a $1 billion private convertible senior notes offering (Globe Newswire), triggering an 8.56% intraday decline from $188.64 to $172.49.
- Repligen completed its acquisition of BioLife Solutions, announced today via Globe Newswire and formalized in an SEC 8-K filing.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RGEN
In-depth RGEN event analyses
Frequently asked questions about RGEN
Why did Repligen Corporation (RGEN) stock move?
Repligen Corporation (RGEN) rose 6.5% on November 18, 2026, closing at $172.67 versus $162.18 the prior session (close-to-close, from daily closes). We checked news, earnings, analyst updates, filings, and corporate actions — no major company-specific catalyst was found. Volume was 1.8x the 5-day average, modestly elevated; a minor institutional position establishment (Ethic Inc. acquiring ~3,054 shares) was noted but does not explain the magnitude of the move. Source: FMP price data; BestStocks detection.
How much did RGEN stock fall?
RGEN lost 0.75% ($1.30) versus the prior close of $172.67, last trading at $171.37 on 0.4× average volume.
When is Repligen Corporation's next earnings date?
RGEN's next earnings report is estimated for 2027-02-23 — about 96 days away.
What is the analyst price target for RGEN?
The consensus analyst price target for RGEN is $198.00, about 15.5% above the current $171.37. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks RGEN
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
